Why take this course?
Artificial intelligence is becoming integrated across regulated GxP activities, including quality systems, manufacturing support, laboratories, clinical operations, and regulatory processes. Unlike deterministic software, AI systems may produce variable outputs influenced by probabilistic models, performance drift, bias, hallucinations, and changing data. These characteristics require organizations to rethink how acceptance criteria are established and how reliability is evaluated before AI-enabled systems are used within regulated operations.
This webinar examines practical approaches for defining meaningful, risk-based acceptance criteria for AI-enabled GxP systems while supporting FDA, EMA, MHRA, GAMP®, and data integrity expectations. Participants will evaluate measurable standards for reliability, consistency, explainability, traceability, auditability, human review, and exception handling. The session also addresses risk management, governance, lifecycle monitoring, and validation strategies that move beyond traditional deterministic approaches while supporting ongoing oversight as AI systems evolve after deployment.
Key Areas Covered
Carolyn Troiano
Carolyn Troiano has more than 45 years of experience in computer system validation across pharmaceutical, biotechnology, medical device, tobacco, and other FDA-regulated industries. Her work in FDA compliance, Computer System Validation, 21 CFR Part 11, data integrity, and large-scale system implementation directly supports organizations validating AI-enabled GxP systems and defining reliable acceptance criteria.
Commonly Asked Questions About This Subject
How should acceptance criteria change when the same AI application is used for both low-risk and high-risk GxP activities?
A single set of acceptance criteria should not automatically be applied across every intended use. Inspection discussions often begin when reviewers discover that one validated AI application supports activities with very different consequences, yet the organization evaluated all uses against identical performance expectations.
An AI tool that assists with drafting internal meeting notes presents a different level of risk than one supporting batch review, deviation investigations, laboratory data interpretation, or regulatory submissions. Validation evidence should reflect those differences.
Documentation becomes difficult to defend when intended use expands over time without reevaluating acceptance criteria. Teams frequently validate the application once, then gradually introduce additional use cases that were never included in the original assessment.
Evidence that carries weight includes documented justification for each intended use, risk-specific performance expectations, clear operational boundaries, and records showing that new applications undergo additional evaluation before being adopted within regulated activities.
What makes an AI validation package appear complete while still failing to demonstrate reliability?
Documentation concern: validation packages often contain extensive testing records, protocols, and approvals while providing little evidence that the system will continue performing reliably under routine operational conditions.
Inspection friction develops when testing relies almost entirely on expected or well-structured inputs. AI systems frequently behave differently when presented with ambiguous information, incomplete context, conflicting records, unusual terminology, or situations outside normal operating conditions.
Reviewers generally look for evidence that the organization intentionally challenged the system rather than simply confirmed successful operation. Validation records become stronger when they demonstrate how unexpected responses were evaluated, what limitations were identified, and which operating boundaries were established.
Reliability is generally supported by thoughtful challenge testing, documented limitations, predefined response criteria for unexpected behavior, and evidence that the system remains suitable for its intended use rather than by the volume of completed validation documentation.
How should organizations respond when an AI system continues meeting validation criteria but its operational performance gradually changes?
An operational failure point emerges when validation is viewed as a permanent conclusion rather than an ongoing assessment. AI applications may continue satisfying original acceptance thresholds while gradually producing outputs that differ in subtle but meaningful ways from historical performance.
Inspection concerns often arise after users report increasing inconsistencies that were never formally evaluated because performance metrics remained within predefined limits. Small changes in output quality, consistency, terminology, or recommendation patterns may signal a gradual shift that deserves investigation.
Documentation becomes less persuasive when operational observations remain informal or are handled outside the quality system. Those experiences often provide the earliest indication that additional evaluation is warranted.
Well-controlled programs periodically compare current performance with historical expectations, investigate unexplained shifts, document observed changes, and reassess whether existing acceptance criteria continue to represent reliable performance within the intended GxP environment.
What is the weakest justification for accepting AI-generated output during a validation review?
A direct answer is that past success alone is a weak basis for acceptance. Statements such as "the system has always been accurate" or "we have never experienced a problem" provide little support during inspection because they describe historical experience rather than objective validation evidence.
Reviewers generally expect organizations to explain why specific outputs were considered acceptable, what evaluation was performed, what uncertainties were identified, and how the conclusion was supported. Confidence based primarily on prior performance often becomes difficult to defend when unusual situations occur.
Records become substantially stronger when acceptance decisions are tied to predefined criteria, documented evidence, representative testing, identified limitations, and traceable rationale. Those elements demonstrate that the organization reached its conclusions through a controlled evaluation process rather than through familiarity or historical trust in the application.
Your TalkFDA Webinar Experience
1. Confirmation
3. Join the Live Training
4. Watch Again Anytime
Testimonials
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.


